IL153804A0 - Tyrosine derivatives as phosphatase inhibitors - Google Patents
Tyrosine derivatives as phosphatase inhibitorsInfo
- Publication number
- IL153804A0 IL153804A0 IL15380401A IL15380401A IL153804A0 IL 153804 A0 IL153804 A0 IL 153804A0 IL 15380401 A IL15380401 A IL 15380401A IL 15380401 A IL15380401 A IL 15380401A IL 153804 A0 IL153804 A0 IL 153804A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- phosphatase inhibitors
- tyrosine derivatives
- diabetes mellitus
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21620100P | 2000-07-06 | 2000-07-06 | |
PCT/US2001/041271 WO2002004412A2 (fr) | 2000-07-06 | 2001-07-05 | Preparation d'inhibiteurs de phosphatase |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153804A0 true IL153804A0 (en) | 2003-07-31 |
Family
ID=22806135
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15380401A IL153804A0 (en) | 2000-07-06 | 2001-07-05 | Tyrosine derivatives as phosphatase inhibitors |
IL153804A IL153804A (en) | 2000-07-06 | 2003-01-05 | Tyrosine derivatives and pharmaceutical preparations containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL153804A IL153804A (en) | 2000-07-06 | 2003-01-05 | Tyrosine derivatives and pharmaceutical preparations containing them |
Country Status (15)
Country | Link |
---|---|
US (1) | US6586467B2 (fr) |
EP (1) | EP1301474B1 (fr) |
JP (1) | JP2004502754A (fr) |
KR (1) | KR100788510B1 (fr) |
AT (1) | ATE407923T1 (fr) |
AU (2) | AU7818801A (fr) |
BR (1) | BR0112216A (fr) |
CA (1) | CA2416220C (fr) |
DE (1) | DE60135752D1 (fr) |
ES (1) | ES2312461T3 (fr) |
IL (2) | IL153804A0 (fr) |
MX (1) | MXPA03000166A (fr) |
NO (1) | NO20030061L (fr) |
NZ (1) | NZ523483A (fr) |
WO (1) | WO2002004412A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020169157A1 (en) * | 2000-08-29 | 2002-11-14 | Gang Liu | Selective protein tyrosine phosphatatase inhibitors |
US20040191926A1 (en) * | 2001-09-26 | 2004-09-30 | Zhong-Yin Zhang | Ptp1b inhibitors and ligands |
WO2004071448A2 (fr) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Derives d'azole substitues comme agents therapeutiques |
JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ,インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
CN1922151A (zh) * | 2004-02-12 | 2007-02-28 | 特兰斯泰克制药公司 | 取代的吡咯衍生物、组合物和使用方法 |
WO2005114197A2 (fr) * | 2004-04-15 | 2005-12-01 | Albert Einstein College Of Medicine Of Yeshiva University | Sondes à activité pour les protéines tyrosine phosphatase |
AU2007211319B9 (en) | 2006-01-30 | 2012-05-31 | Vtv Therapeutics Llc | Substituted imidazole derivatives and their use as PTPase inhibitors |
EP2601946A1 (fr) * | 2011-12-06 | 2013-06-12 | Pécsi Tudomànyegyetem | Traitement et prévention des maladies liées au stress oxydatif |
WO2013142010A1 (fr) * | 2012-03-20 | 2013-09-26 | Temple University - Of The Commonwealth System Of Higher Education | Dérivés de 3-aminothieno[3,2-c]quinoline, procédés de préparation et utilisations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707559A (en) * | 1971-05-14 | 1972-12-26 | Searle & Co | N-acyl phenylalanine amides |
DE69116576T2 (de) * | 1991-09-05 | 1996-10-10 | Pharno Wedropharm Gmbh | Aromatische sulfonamidderivate, ihre verwendung als enzyminhibitoren und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE4425781A1 (de) * | 1994-07-14 | 1996-01-18 | Schering Ag | Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel |
DE69824433D1 (en) * | 1997-08-28 | 2004-07-15 | Biovitrum Ab | Proteintyrosinphosphatase inhibitoren |
US6410585B1 (en) * | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
JPH11246511A (ja) * | 1998-02-25 | 1999-09-14 | Kanebo Ltd | 硫酸エステル誘導体 |
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
WO2002063299A1 (fr) * | 2001-02-05 | 2002-08-15 | Graffinity Pharmaceuticals Ag | Procede de criblage des faibles affinites |
-
2001
- 2001-07-05 IL IL15380401A patent/IL153804A0/xx unknown
- 2001-07-05 US US09/899,654 patent/US6586467B2/en not_active Expired - Fee Related
- 2001-07-05 DE DE60135752T patent/DE60135752D1/de not_active Expired - Lifetime
- 2001-07-05 AT AT01956161T patent/ATE407923T1/de not_active IP Right Cessation
- 2001-07-05 AU AU7818801A patent/AU7818801A/xx active Pending
- 2001-07-05 EP EP01956161A patent/EP1301474B1/fr not_active Expired - Lifetime
- 2001-07-05 NZ NZ523483A patent/NZ523483A/en not_active IP Right Cessation
- 2001-07-05 MX MXPA03000166A patent/MXPA03000166A/es active IP Right Grant
- 2001-07-05 AU AU2001278188A patent/AU2001278188B2/en not_active Ceased
- 2001-07-05 CA CA2416220A patent/CA2416220C/fr not_active Expired - Fee Related
- 2001-07-05 BR BR0112216-9A patent/BR0112216A/pt not_active IP Right Cessation
- 2001-07-05 ES ES01956161T patent/ES2312461T3/es not_active Expired - Lifetime
- 2001-07-05 KR KR1020037000196A patent/KR100788510B1/ko not_active IP Right Cessation
- 2001-07-05 JP JP2002509079A patent/JP2004502754A/ja not_active Ceased
- 2001-07-05 WO PCT/US2001/041271 patent/WO2002004412A2/fr active IP Right Grant
-
2003
- 2003-01-05 IL IL153804A patent/IL153804A/en not_active IP Right Cessation
- 2003-01-06 NO NO20030061A patent/NO20030061L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR100788510B1 (ko) | 2007-12-24 |
NO20030061L (no) | 2003-03-05 |
MXPA03000166A (es) | 2004-09-13 |
US20020040003A1 (en) | 2002-04-04 |
DE60135752D1 (en) | 2008-10-23 |
CA2416220C (fr) | 2010-04-06 |
ATE407923T1 (de) | 2008-09-15 |
WO2002004412A3 (fr) | 2002-08-22 |
ES2312461T3 (es) | 2009-03-01 |
AU2001278188B2 (en) | 2007-05-17 |
KR20030029613A (ko) | 2003-04-14 |
CA2416220A1 (fr) | 2002-01-17 |
JP2004502754A (ja) | 2004-01-29 |
WO2002004412A2 (fr) | 2002-01-17 |
NO20030061D0 (no) | 2003-01-06 |
US6586467B2 (en) | 2003-07-01 |
NZ523483A (en) | 2004-08-27 |
IL153804A (en) | 2009-12-24 |
BR0112216A (pt) | 2004-02-10 |
AU7818801A (en) | 2002-01-21 |
EP1301474A2 (fr) | 2003-04-16 |
EP1301474B1 (fr) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO2372B1 (en) | Source drugs of 4-phenylpyridine derivatives | |
WO2004056786A3 (fr) | Composes pour traiter le developpement anormal de cellules | |
MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
WO2001064639A3 (fr) | Amides inhibant la pde iv, compositions et procedes de traitement | |
WO2002057252A3 (fr) | Inhibiteurs sulfonamides heterocycliques de la production de beta-amyloide | |
WO2001098277A3 (fr) | Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale | |
IL157254A0 (en) | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists | |
MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
MXPA05012837A (es) | Inhibidores de caspasa y usos de los mismos. | |
GEP20074045B (en) | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease | |
IL153804A0 (en) | Tyrosine derivatives as phosphatase inhibitors | |
MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
WO2001081316A3 (fr) | Inhibiteurs de phenyle farnesyltransferase substitues | |
WO2007014839A3 (fr) | Inhibiteurs de la cathepsine k | |
DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
EP1109560A4 (fr) | Composes utiles en tant qu'inhibiteurs d'aicarft | |
RS44004A (en) | Processes for the preparation of substituted bicyclid derivatives for the treatment of abnormal cell growth | |
AU2368802A (en) | Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence | |
WO2003028652A3 (fr) | Utilisation de benzopyranones pour le traitement ou la prevention d'un cancer primitif du cerveau ou d'une metastase cerebrale | |
AP2002002669A0 (en) | Hygromycin a derivatives for the treatment of bacterial and protozoal infections. | |
UA81405C2 (en) | Substituted pyridinones as modulators of p38 map kinase | |
WO2003090737A3 (fr) | Methodes et compositions de traitement de la douleur cancereuse | |
AU2001235669A1 (en) | Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis |